

Author: Silvestre J-S. Robert V. Escoubet B. Heymes C. Oubénaïssa A. desopper C. Swynghedauw B. delcayre C.
Publisher: Academic Press
ISSN: 0022-2828
Source: Journal of Molecular and Cellular Cardiology, Vol.32, Iss.7, 2000-07, pp. : 1249-1263
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This study analysed the regulation of cardiac mineraloreceptor (MR) and glucoreceptor (GR) in aldosterone-salt treatment (AST). AST causes hypertension, left ventricle (LV) hypertrophy and decreases plasma corticosterone level. Ribonuclease protection assay and Western blot analysis showed a rise of MR mRNA (1.5- and 1.4-fold at day 15 and 30, respectively) and protein levels (1.8- and 4.1-fold at day 30 and 60, respectively) in the LV, but not in either the right ventricle (RV) or in kidney of treated rats. Addition of MR antagonist spironolactone (20 mg/kg/day) for 30 days failed to prevent these changes but was able to reduce AST-induced cardiac fibrosis. Similar hypertension-induced MR upregulations were observed in the LV of AngII-hypertensive rats and of 12-week-old SHR when compared to 4-week-old prehypertensive SHR. AST also enhanced left ventricular GR mRNA (2.0- and 3.0-fold at day 7 and 15, respectively) and protein contents (2.0- and 1.7-fold at day 30 and 60, respectively). In contrast to MR, GR levels were also upregulated in both RV and kidney. Such an upregulation was equally observed at mRNA and protein levels in LV, RV and kidney after adrenalectomy (15 days) and was prevented in both tissues after glucocorticoid replacement (adrenalectomy + dexamethasone at 100
Related content




By Rodrigo Ramón Rivera Gonzalo Lucero Yalola Larraguibel Constanza
Endocrine Journal, Vol. 19, Iss. 3, 2002-12 ,pp. :






Aldosterone and Resistant Hypertension
Current Hypertension Reviews, Vol. 3, Iss. 2, 2007-05 ,pp. :